IMMUNOTHERAPY OF MALIGNANT DISEASES OF B-CELLS AND AUTOIMMUNE DISEASES WITH APPLICATION OF CONJUGATE AND NONCONJUGATE ANTIBODIES, COMBINATIONS OF ANTIBODIES AND CONJOINT PROTEINS Russian patent published in 2008 - IPC A61K39/00 A61K39/395 A61K41/00 A61K51/10 A61P35/00 A61P37/06 

FIELD: medicine.

SUBSTANCE: invention is referred to medicine area, namely, to an immunotherapy. Application (i) of conjugate anti-CD74-antibodies and non-conjugate anti-CD20-antibody merged with a protein anti-CD20-antibody which contains an antigen-binding molecule with two or more segments of identical or various one-chained antibodies or fragments of antibodies are bound to identical or various specificity, or an anti-CD20-antibody fragment, or (ii) conjugate anti-CD20-antibodies and non-conjugate anti-CD74-antibody merged with an anti-CD74-antibody of fiber which contains a molecule produced by recombinant antigen-binding with two or more segments of identical or various one-chained antibodies or fragments of antibodies are bound to identical or various specificity, or an anti-CD74-antibody fragment, in manufacture of a medical product for treatment at the mammal malignant disease bound to B-cells, the disease bound to T-cells, or autoimmune disease is offered. The combination of anti-CD74 - and anti-CD-20 of-antibodies as it is declared in the present invention, provides increase of immunotherapy efficiency without collateral toxic effects.

EFFECT: increase of immunotherapy efficiency at treatment of malignant diseases without collateral toxic effects.

39 cl, 4 ex